Abbvie

This program offers early access to the investigational drug ABBV-706 for people with small cell lung cancer who have no other suitable treatment options and cannot join a clinical trial. A doctor must decide if the potential benefits outweigh the risks. The goal is to provide tr…

This study tests an investigational drug called MEDI0618 to see if it can safely reduce the number of migraine headache days in adults with episodic migraine. About 488 participants will receive either the drug or a placebo as a shot under the skin. The goal is to find out if the…

This program offers early access to tavapadon, an investigational drug for Parkinson's disease, before it is officially approved. It is for people who have no other suitable treatment options and cannot join ongoing clinical trials. A doctor must decide if the potential benefits …

This study tests an experimental oral medication, upadacitinib, in children aged 1 to 17 with systemic juvenile idiopathic arthritis (sJIA), a rare and serious form of arthritis that can affect the whole body. About 90 participants will receive either upadacitinib or the standard…

This study tests a new drug combination (carboplatin plus mirvetuximab soravtansine) given before surgery to people with advanced ovarian, fallopian tube, or peritoneal cancer that has a specific protein (FRα). The goal is to see if the treatment shrinks tumors enough to improve …

This study follows 200 adults with moderate to severe ulcerative colitis who are prescribed risankizumab by their doctors in Germany and Austria. Researchers will track how well the drug controls symptoms like bleeding and frequent bowel movements over 52 weeks. The goal is to se…

This study tests an oral medication, upadacitinib, in children aged 2 to 18 with moderate-to-severe Crohn's disease who haven't improved with standard treatments. The goal is to see if the drug can reduce inflammation and improve symptoms. Participants will take the drug daily an…

This study looks at how to safely start a combination of drugs (venetoclax plus obinutuzumab or acalabrutinib) in people with untreated chronic lymphocytic leukemia (CLL). The main goal is to find the best way to increase the dose of venetoclax over time to reduce the risk of a s…

This study compares two approved drugs, risankizumab and vedolizumab, to see which works better for adults with moderate to severe ulcerative colitis who haven't tried targeted therapies before. About 530 participants will receive one of the two medications, and researchers will …

This study tests a new investigational drug called telisotuzumab adizutecan combined with standard chemotherapy and targeted therapies for people with metastatic colorectal cancer (cancer that has spread). About 390 adults will receive either the new drug at different doses or st…

This study follows about 240 people in Japan with moderate to severe Crohn's disease who are taking the approved drug upadacitinib. Researchers will track side effects and how well the drug controls the disease over up to 64 weeks. The goal is to see how the drug works in everyda…

This study follows about 1,200 adults with psoriatic arthritis to see how long they stay on risankizumab compared to other advanced treatments. Participants receive their usual prescribed care, and researchers track treatment persistence and effectiveness over 24 months. The goal…

This study looks at how well the drug Foslevodopa/Foscarbidopa works for people with advanced Parkinson's disease in everyday medical practice in Belgium. About 120 adults who are already prescribed this drug by their doctor will take part and be followed for up to 18 months. The…

This study tests whether a new combination of two experimental drugs (livmoniplimab and budigalimab) plus chemotherapy works better than the current standard treatment (pembrolizumab plus chemotherapy) for people with untreated metastatic non-squamous non-small cell lung cancer. …

This study tests whether giving a second course of the drugs venetoclax and obinutuzumab can help adults whose chronic lymphocytic leukemia (CLL) has returned after an earlier successful treatment. About 75 participants will receive the drugs in cycles over 12 to 24 months. Resea…

This study tests an experimental drug called telisotuzumab vedotin in adults with a specific type of advanced lung cancer (non-small cell lung cancer) that has a high level of a protein called c-Met. About 150 participants will receive one of three different doses of the drug to …

This study looks at how well the drug upadacitinib (RINVOQ) controls symptoms of ulcerative colitis, a condition that causes inflammation and bleeding in the colon. About 400 adults in Germany, Austria, and Switzerland who are already prescribed the drug will be followed for up t…

This study tests an experimental drug called IMGN151 for people with gynecologic cancers, including ovarian cancer. The drug is given alone or with other cancer treatments to see if it is safe and works. About 377 adults will take part at sites worldwide. The goal is to find bett…

This study tests two experimental drugs, etentamig and iberdomide, together in adults whose multiple myeloma has returned or stopped responding to treatment. The goal is to find safe doses and see if the combination can shrink the cancer. About 135 participants will receive diffe…

This early-phase study tests an experimental drug called ABBV-969 in men with a hard-to-treat form of advanced prostate cancer (mCRPC). The main goals are to check safety, find the right dose, and see if it lowers PSA levels. About 230 participants worldwide will receive the drug…

This study tests how well a drug called Foslevodopa/Foscarbidopa helps people with early advanced Parkinson's disease. It will include 125 adults in Germany who are already prescribed this drug by their doctor. The goal is to see if it improves movement, quality of life, and dail…

This study tests a new drug called etentamig combined with daratumumab for people newly diagnosed with multiple myeloma who are not healthy enough for a stem cell transplant. About 660 adults will receive either the new combination or standard treatment. The goal is to see if the…

This early-phase study tests an investigational drug called ABBV-319 in 36 adults with lupus or Sjogren's disease. The drug is designed to temporarily reduce certain immune cells (B cells) that are overactive in these conditions. Participants receive two doses by IV, 21 days apar…

This study follows about 200 adults in Japan with moderate to severe ulcerative colitis who are prescribed risankizumab by their doctors as part of routine care. Researchers will track changes in disease activity, like stool frequency and rectal bleeding, for up to 156 weeks. The…

This study tests a drug called risankizumab in children aged 2 to 18 with moderate to severe ulcerative colitis, a condition causing colon inflammation and bleeding. The trial will check how the drug works in the body, its safety, and its ability to reduce symptoms. Around 120 ch…

This early-phase study tests an experimental drug called ABBV-324 in about 232 adults with liver cancer (hepatocellular carcinoma) or a type of lung cancer (squamous non-small cell lung cancer). The main goals are to check safety, side effects, and whether the drug shrinks tumors…

This study tests a combination of two drugs, venetoclax and azacitidine, in about 100 Indian adults newly diagnosed with acute myeloid leukemia (AML) who are not healthy enough for standard intensive chemotherapy. The goal is to see how well the combo controls the cancer and what…

This study tests a daily pill called upadacitinib for people with moderate to severe hidradenitis suppurativa (HS) who haven't improved with other treatments. About 1,328 adults and teens will receive either the drug or a placebo for up to 104 weeks to see if it reduces painful l…

This study looks at how upadacitinib, an approved eczema drug, works in real-world settings for about 1,000 teens and adults with moderate to severe atopic dermatitis in China. Participants take the drug as prescribed by their doctor and are followed for 12 months. The goal is to…

This study tests whether a new drug called telisotuzumab vedotin works better than a standard chemotherapy (docetaxel) for adults with a specific type of advanced non-small cell lung cancer that has a high level of a protein called c-Met. About 698 participants worldwide will be …

This study tests an experimental drug called telisotuzumab adizutecan in people aged 12 and older whose solid tumors have a specific genetic change (MET amplification). The goal is to see if the drug can shrink tumors and to check for side effects. Participants receive the drug t…

This study tests a drug called venetoclax in about 14 adults in Japan who have a rare blood cancer (Waldenström macroglobulinemia) that has returned or not responded to prior therapy. Participants take venetoclax pills daily for up to 28 months. The goal is to see if the drug can…

This study tests an experimental drug called surzetoclax (ABBV-453) in about 130 adults with multiple myeloma that has returned or stopped responding to prior treatments. The drug is given alone or combined with other anti-myeloma medicines. The main goals are to check safety and…

This study tests a daily pill called upadacitinib for people with severe alopecia areata, a condition where the immune system attacks hair follicles, causing significant hair loss. About 123 adults and teens in Japan with at least 25% scalp hair loss will take either the drug or …

This early-phase study tests an experimental drug called ABBV-711, alone or with another drug (budigalimab), in adults with advanced squamous tumors (like certain lung or head/neck cancers) that have stopped responding to standard treatments. The main goals are to check safety, f…

This study tests a one-time gene therapy called RGX-314 for wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if it can control the disease as well as standard treatments that require eye injections every few months. About 714 adults a…

This study tests two drugs, risankizumab and lutikizumab, alone or together, in adults with active psoriatic arthritis (PsA). PsA causes joint pain and swelling due to the immune system attacking healthy tissue. About 120 participants will be randomly assigned to one of three tre…

This study will follow about 678 adults with moderate to severe rheumatoid arthritis in Germany to see how long they stay on either upadacitinib (UPA) or a TNF inhibitor (TNFi). The goal is to compare treatment retention rates in real-world settings, not a controlled lab. Partici…

This study looks at how well the drug upadacitinib works in real-world settings for people with axial spondyloarthritis, a type of arthritis that mainly affects the spine and causes chronic back pain. About 352 adults in Germany will take the pill as their doctor prescribes and b…

This study tests an oral drug called upadacitinib for people with severe alopecia areata, a condition where the immune system attacks hair follicles, causing hair loss. About 1,500 adults and teens worldwide will take either the drug or a placebo daily for up to 160 weeks. The go…

This study tests a new medicine called ABBV-6628 for people with geographic atrophy, an advanced form of dry age-related macular degeneration that causes vision loss. About 66 adults aged 50 and older will receive injections into the eye, either with the new drug or an approved t…

This early-stage study tests a new drug called azirkitug, alone or with other medicines, in people with advanced solid tumors like lung, head/neck, and other cancers. The goal is to find safe doses and check side effects. About 694 adults will take part at sites worldwide.

This study tests an experimental drug called ABBV-142 for idiopathic pulmonary fibrosis (IPF), a rare disease that scars the lungs and makes breathing hard. About 165 adults with IPF will receive either ABBV-142 or a placebo for 52 weeks to see if it safely slows lung function de…

This study tests an experimental drug, telisotuzumab adizutecan, against standard care in about 430 adults with a specific type of advanced lung cancer (EGFR-mutated non-squamous non-small cell lung cancer) that has worsened after using a third-generation targeted therapy. The go…

This program offers early access to telisotuzumab adizutecan for people with solid tumors who have no other suitable treatment options and cannot join a clinical trial. A doctor must decide if the potential benefit outweighs the risks. The drug is not yet approved by local regula…

This program provides early access to upadacitinib for people with Crohn's disease, ulcerative colitis, certain types of arthritis, or atopic dermatitis. It is for those who have no other suitable treatment options and cannot join a clinical trial. A doctor must decide if the pot…

This study tests a new drug combination (telisotuzumab adizutecan, budigalimab, and two standard chemotherapies) as a first treatment for adults with advanced stomach, gastroesophageal junction, or esophageal cancer that cannot be removed by surgery. About 180 participants will r…

This study tests whether adding an experimental drug (telisotuzumab adizutecan) to a standard targeted therapy (osimertinib) works better than standard care for advanced non-small cell lung cancer with an EGFR mutation. About 854 adults will receive different doses of the combina…

This early-stage study tests an experimental drug called ABBV-438 in about 127 adults whose multiple myeloma has returned or stopped responding to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink the cancer. Particip…

This study compares two medicines—upadacitinib (a daily pill or liquid) and dupilumab (shots every 2 or 4 weeks)—in about 675 children aged 2 to 12 with moderate to severe eczema that isn't controlled by creams. The goal is to see which treatment better reduces skin redness, itch…

This study tests a new drug, telisotuzumab adizutecan, combined with an immunotherapy drug (a PD-1 checkpoint inhibitor) in people with advanced non-squamous non-small cell lung cancer who have not had prior treatment for advanced disease. The goal is to find the best dose that i…

This study tests four targeted medicines (risankizumab, trosunilimab, lutikizumab, and ABBV-8736) in about 540 adults with moderate to severe Crohn's disease. The goal is to see if these drugs can reduce gut inflammation and improve symptoms better than current treatments. Partic…

This study tests if the drug atogepant can safely prevent chronic migraines in teenagers aged 12 to 17. About 420 teens will take either atogepant or a placebo daily for 12 weeks. The goal is to see if the drug reduces the number of migraine days and is safe for this age group.

This program provides early access to venetoclax, a targeted therapy for several blood cancers including chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and multiple myeloma. It is for people who have no other suitable treatments and cannot join a clinical trial…

This study tests a drug called venetoclax in people whose chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) has come back or stopped responding to other treatments. About 110 participants will receive the drug to see if it shrinks their cancer. The goal is to…

This study tests whether the drug atogepant can prevent menstrual migraines—headaches that strike around your period. About 430 women with regular cycles and a history of migraine will take either atogepant or a placebo pill daily for 3 menstrual cycles. The goal is to see if the…

This study tests an experimental drug called etentamig (ABBV-383) in adults with multiple myeloma that has returned or not improved after prior treatments. The goal is to find the best dose and check for side effects. About 210 participants will receive the drug by IV infusion ov…

This study tests whether upadacitinib, a daily pill, can help adults with moderate to severe eczema (atopic dermatitis) who did not get enough relief from dupilumab injections. About 200 participants will receive upadacitinib or continue dupilumab for 32 weeks. The main goal is t…

This study tests a gene therapy called ABBV-RGX-314 for people with wet age-related macular degeneration (nAMD), a leading cause of vision loss. About 561 adults aged 50 and older will receive either a single gene therapy injection or standard anti-VEGF shots as needed. The goal …

This study tests an experimental drug, etentamig, for adults with multiple myeloma, a blood cancer that often returns or resists treatment. About 440 participants worldwide will receive etentamig alone or combined with other cancer drugs to find safe doses and check if it shrinks…

This study follows about 700 adults with advanced diffuse large B-cell lymphoma or follicular lymphoma who are receiving epcoritamab as part of their routine care. Researchers will track how well the drug works in real-world settings over up to 3 years. The goal is to see how man…

This study tests an experimental eye injection called AGN-193408 SR in people with open-angle glaucoma or high eye pressure. The goal is to see if it safely lowers pressure inside the eye, which can prevent vision loss. About 96 adults who have had cataract surgery at least 4 mon…

This early-phase study tests an investigational drug called ABBV-901, given alone or with a standard drug (bevacizumab), in about 207 adults with advanced ovarian cancer that no longer responds to platinum chemotherapy. The main goals are to check safety and see if tumors shrink.…

This study tests a new drug, ABBV-706, combined with atezolizumab against standard treatment for people with extensive-stage small cell lung cancer that hasn't been treated yet. About 180 adults will receive either the new combination or standard care to find the best dose and se…

This study tests an experimental drug, etentamig (ABBV-383), in about 76 adults with AL amyloidosis, a rare disease where abnormal proteins build up in organs. The drug aims to reduce these proteins by targeting the bone marrow cells that produce them. Participants receive the dr…

This study is testing a material called ARTIA, used to support breast implants during reconstruction after mastectomy. About 783 adults who need immediate two-stage breast reconstruction will receive either ARTIA or standard care. The goal is to see if ARTIA reduces major complic…

This study tests an experimental drug called mirvetuximab soravtansine (MIRV) combined with either bevacizumab or carboplatin in people with a specific type of ovarian cancer. About 320 participants will receive different doses to find the safest and most effective treatment. The…

This early-stage study tests a new drug called ABBV-295 in 96 adults with obesity. Participants receive multiple injections of the drug or a placebo to check for side effects, how the drug moves through the body, and any weight changes. The goal is to gather safety information be…

This study tests a drug called mirvetuximab soravtansine (MIRV) in people with a type of ovarian cancer that no longer responds to platinum chemotherapy. The drug targets a protein (FRα) on cancer cells to deliver a cell-killing agent. About 110 participants will receive MIRV on …

This study tracks 250 adults with moderate-to-severe Crohn's disease who are switching to a second treatment (upadacitinib or risankizumab) after their first therapy stopped working well. Researchers will see if these drugs help patients achieve remission without needing steroids…

This early-stage study tests a new drug, ABBV-291, in adults with Non-Hodgkin's lymphoma that has returned or not responded to treatment. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. About 165 participants will receive the drug throu…

This study tests if a daily pill called ubrogepant can prevent migraines that happen around a woman's period. About 496 women with menstrual migraines will take the pill or a placebo for 7 days each cycle. The goal is to see if it reduces the number of migraine days and is safe t…

This early-stage study tests an experimental drug called ABBV-319 in adults with B-cell cancers (lymphomas and leukemia) that have come back or not responded to treatment. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. About 154 parti…

This study tests an investigational drug called ABBV-CLS-628 in adults with autosomal dominant polycystic kidney disease (ADPKD), a genetic condition that causes fluid-filled cysts to grow in the kidneys. About 240 participants will receive either the drug or a placebo by IV ever…

This study tests if Armour Thyroid, a natural thyroid extract, works as well as the standard synthetic T4 medication for adults with hypothyroidism (underactive thyroid). About 2,800 people currently stable on synthetic T4 will switch to Armour Thyroid or stay on their current dr…

This study tests a drug called risankizumab in children aged 2 to 18 with moderate to severe Crohn's disease. The goal is to see if it can reduce gut inflammation and improve symptoms like belly pain and diarrhea. Participants will receive the medicine through an IV or injection …

This study tests whether adding mirvetuximab soravtansine to standard maintenance therapy (bevacizumab) can delay cancer regrowth in people with a specific type of ovarian, fallopian tube, or peritoneal cancer. Participants must have cancer that responded to initial platinum-base…

This study tests three new treatments for adults with moderate to severe rheumatoid arthritis (RA) who have not improved with at least one prior therapy. Participants will receive either a single drug (lutikizumab or ravagalimab), a combination of both, or a placebo. The goal is …

This program offers early access to elezanumab, an investigational drug, for people with acute spinal cord injury who have no other suitable treatment options and cannot join ongoing clinical trials. A doctor must decide if the potential benefit outweighs the risks. The drug is n…

This study tests whether atogepant, a drug already approved for adults, can safely prevent migraines in children aged 6 to 17. About 450 participants will take a daily tablet (low-dose, high-dose, or placebo) for 12 weeks. The goal is to reduce the number of migraine days each mo…

This study tests a new drug, telisotuzumab adizutecan, against standard care in about 140 adults with colorectal cancer who have completed initial treatment but still have cancer DNA in their blood (ctDNA positive) with no visible tumors on scans. The goal is to see if the new dr…

This study tests a gel stent device to lower eye pressure in people with glaucoma, a leading cause of blindness. About 130 adults aged 45 and older will get the stent placed either inside or outside the eye. Researchers will check safety and how well it reduces eye pressure over …

This study follows about 80 Chinese adults with moderate to severe ulcerative colitis who are already prescribed upadacitinib by their doctor. Researchers will track how well the drug controls symptoms like bloody diarrhea over one year, using only routine checkup data. The goal …

This study tests a new drug called etentamig against standard treatments for adults with multiple myeloma that has returned or stopped responding. About 380 participants will receive either etentamig or a standard therapy chosen by their doctor. The goal is to see if etentamig ca…

This study is monitoring the long-term safety and effectiveness of the XEN45 implant, a tiny device placed in the eye to lower pressure. It is comparing the implant to a standard glaucoma surgery (trabeculectomy) in about 130 adults in China who have open-angle glaucoma. The main…

This study is testing whether a new drug called risankizumab is safe and effective for treating juvenile psoriatic arthritis, a condition where the immune system attacks joints and skin. About 40 children worldwide will receive either risankizumab or an approved drug called adali…

This study is checking the safety and effectiveness of atogepant, a drug already approved for migraine prevention, in Korean adults. About 3000 people with chronic or episodic migraines will take the drug as prescribed by their doctor and be followed for up to 12 weeks. The goal …

This study looks at how well the drug Foslevodopa/Foscarbidopa works for Italian adults with advanced Parkinson's disease in everyday medical practice. About 270 participants will receive the drug as a continuous infusion under the skin for up to 12 months. The main goal is to se…

This study tests a new artificial tear, ABBV-444, against an existing brand (Refresh Optive) in 250 adults with dry eye disease. Participants use the assigned drops for 90 days. The goal is to see if the new formula improves eye comfort and reduces dryness symptoms better than th…

This study tests a new drug, icalcaprant, for people with major depression. About 195 adults will take either the drug or a placebo daily for 6 weeks. The goal is to see if it reduces depression symptoms and is safe. Participants will have regular check-ups and questionnaires.

This study looks at whether taking the migraine drug ubrogepant during the earliest signs of a migraine (called the prodrome phase) can prevent moderate to severe headache pain. About 189 adults who already use ubrogepant will take it as prescribed and report their symptoms over …

This study follows 700 adults with moderate-to-severe plaque psoriasis who are already prescribed risankizumab by their doctor. Researchers will measure how the drug affects quality of life, including skin symptoms and daily activities, over up to 2.5 years. Participants continue…

This study looks at how well the migraine prevention drug atogepant works for adults in real-world settings. About 1000 people who are already prescribed atogepant by their doctor will be followed for 2 years. The goal is to see how many feel much better or very much better since…

This study tests an injectable gel called ELAPR002f for adults with moderate to severe indented acne scars on both cheeks. About 395 participants will receive either the gel or a saline placebo over 2 months and be followed for a year. The goal is to see if the gel safely reduces…

This study tests whether ubrogepant, a drug already approved for adults, can safely and effectively treat migraine attacks in children and adolescents aged 6 to 17. About 1,059 participants with a history of migraine will receive either a low or high dose of ubrogepant or a place…

This study tests an experimental drug called icalcaprant for treating depression in people with bipolar I or II disorder. About 195 adults will take either the drug or a placebo daily for 6 weeks. Researchers will measure mood changes using a standard depression scale and track a…

This study tests an experimental drug, emraclidine, in 268 adults with schizophrenia. The goal is to see if it safely reduces symptoms like hallucinations and confused thinking. Participants take the drug or a placebo daily for up to 42 days, with regular check-ups and blood test…

This study tests a new injectable gel called NOA VOLUME against the approved filler JUVÉDERM VOLUMA XC for restoring fullness in the mid-face (cheek area). About 231 adults with moderate to severe volume loss will receive one of the two fillers, with optional touch-ups. The goal …

This study is testing an investigational drug called eluxadoline in children aged 6 to 17 who have irritable bowel syndrome with diarrhea (IBS-D). The goal is to see if the drug can improve stool consistency and reduce symptoms safely. About 95 children will take either the drug …

This study tests whether cariprazine, a drug already approved for adults, can safely ease depressive episodes in children aged 10 to 17 with bipolar I disorder. About 380 participants will receive either the drug or a placebo for 6 weeks, with dose adjustments based on response. …

This study tests the long-term safety of an experimental drug called ABBV-932 for people with bipolar I or II disorder who are currently in a depressive episode. About 200 adults will take the drug daily for 26 weeks and be monitored for side effects, mood changes, and overall he…

This study tests whether adding an experimental drug called ABBV-932 to standard antidepressants can better reduce anxiety in adults with generalized anxiety disorder (GAD) who haven't gotten enough relief from antidepressants alone. About 315 participants will receive either ABB…

This study looks at how to reduce eye problems caused by the drug mirvetuximab soravtansine in people with recurrent ovarian cancer. About 100 participants will receive the drug and be monitored for eye side effects, with some using special eye drops to try to prevent them. The g…

This study looks at whether a continuous infusion of Foslevodopa/Foscarbidopa, given under the skin, can improve sleep disturbances in adults with advanced Parkinson's disease. About 103 participants in Spain will be followed for up to 12 weeks as they receive the treatment as pa…

This early-stage study tests a new drug called ABBV-295 in 24 healthy Japanese adults who are overweight or obese. The main goal is to check the drug's safety and how the body processes it. Participants receive injections, and researchers monitor for side effects. This is a first…

This study tests an investigational drug called AGN-151607-DP (gemibotulinumtoxinA) to see if it can help close the belly wall after open ventral hernia surgery without needing a complex additional procedure. About 200 adults with a midline ventral hernia will receive either the …

This study tests whether atogepant, a drug already approved to prevent migraines, can also stop a migraine attack quickly once it starts. About 1,300 adults with a history of migraines will take either atogepant or a placebo at the start of a migraine and report if their pain goe…

This study tests an investigational drug called lutikizumab for people with moderate to severe hidradenitis suppurativa (HS), a chronic skin disease causing painful lumps and scars. About 1,280 adults and teens will receive either lutikizumab or a placebo for 16 weeks, then all w…

This early-stage study is testing an experimental drug called ABBV-243 in healthy adults to see if it is safe and how the body processes it. About 66 participants will receive either the drug or a placebo, given as an injection or IV. The study does not aim to treat any disease; …

This study looks back at medical records of 2000 people with hepatitis C who took an 8-week treatment called Glecaprevir/Pibrentasvir. The goal is to see how safe and effective the treatment is for those also taking prescription or illegal drugs. Researchers will track side effec…

This study watches pregnant women with migraines who take Ubrelvy or Qulipta, and compares them to pregnant women with migraines who don't take these drugs. Researchers will track the health of mothers and babies up to 12 months after birth. No new treatment is given—participants…

This early-stage study tests a new drug called ABBV-1042 in 48 healthy adults to see if it is safe and how the body processes it. Participants receive either the drug or a placebo, and researchers monitor for side effects and measure drug levels in the blood. This study does not …

This study aims to understand how alopecia areata, vitiligo, and hidradenitis suppurativa affect the daily lives and well-being of teens and adults. Researchers will collect information from nearly 2,800 participants across multiple countries using questionnaires and skin assessm…

This study looks at how doctors around the world use a 'treat-to-target' approach for people with Crohn's disease or ulcerative colitis. Researchers will review medical records from 2,000 adults over 24 months to see if adjusting treatment based on regular check-ups leads to bett…

This early-stage study is testing a new drug, ABBV-547, in healthy adults to see if it is safe and how the body handles it. About 87 participants in the US and Japan will receive a single dose of the drug or a placebo. The study will monitor side effects and measure drug levels i…

This early-stage study looks at how a new drug called ABBV-722 changes the way the body processes five common medications in 12 healthy adults. The goal is to check for safety and measure drug levels in the blood. There is no treatment or cure involved—just gathering important in…

This early-stage study tests how two oral drugs, ABBV-722 and upadacitinib, affect each other in the body. About 32 healthy adults will take both drugs and have blood samples taken to measure drug levels. The main goal is to understand safety and how the drugs are processed, not …

This early-stage study tests the safety and tolerability of emraclidine, an experimental oral drug, in 32 healthy adults aged 65 and older. Participants receive either the drug or a placebo to see how the drug moves through the body and whether it causes side effects. This study …

This study looks at how a new drug called ABBV-722 changes the way birth control pills work in the body. It involves 16 healthy volunteers who will take both the drug and the pill. The goal is to see if the drug affects the levels of the pill's hormones, which could change how we…

This study follows 500 people with chronic lymphocytic leukemia (CLL) who are taking venetoclax alone or with other drugs as part of their normal treatment. Researchers will track how well the cancer responds, side effects, and costs. The goal is to see how the drug performs outs…